Evidence map›Paper›PMID 34439990›Full record

ArticleBiology2021

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.

Isabella Damiani, Silvia Castiglioni, Alicja Sochaj-Gregorczyk, Fabrizia Bonacina, Irma Colombo, Valentina Rusconi, Jacek Otlewski, Alberto Corsini, Stefano Bellosta

Abstract read
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isabella DamianiDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Silvia CastiglioniDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Alicja Sochaj-GregorczykMicrobiology Department, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30387 Krakow, Poland.
Fabrizia BonacinaDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-2611-1177
Irma ColomboDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-9021-3119
Valentina RusconiDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Jacek OtlewskiDepartment of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50137 Wroclaw, Poland.ORCID 0000-0001-8630-2891
Alberto CorsiniDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0002-9912-9482
Stefano BellostaDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0001-5344-7824

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A promising approach for the development of high-affinity tumor targeting ADCs is the use of engineered protein drugs, such as affibody molecules, which represent a valuable alternative to monoclonal antibodies (mAbs) in cancer-targeted therapy. We developed a method for a more efficient purification of the Z

Indexed as

affibodybreast cancerHER2 overexpressiontarget therapy

Identifiers

PMID34439990
PMCPMC8389717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.